2nd Quarter - Report
CELGENE CORPORATION for CELGENE CORPORATION
Firm
Client
Income
—
Expenses
$730,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Issues relating to Patent Reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ALANNA TEMME | — |
Health Issues HCR
H.R. 1730, Cancer Drug Parity Act, regarding all provisions. S. 741, Cancer Drug Parity Act,regarding all provisions. H.R. 2279, Safe Step Act, issues relating to Step Therapy / Fail First. HR 965 / S. 340, CREATES Act, provisions regarding REMS. Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Issues relating to Medicare Reimbursement and Medicare Part D / Part B.
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREG CHESMORE | — |
| HELEN FITZPATRICK New | — |
| PATRICK GLIHA | — |
| STEPHEN RUBRIGHT | — |
| MATTHEW SCHUMAKER | — |
| ALANNA TEMME | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.